Orladeyo
Total Payments
$4.9M
Transactions
5,151
Doctors
1,565
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $593.29 | 47 | 22 |
| 2021 | $2.6M | 4,520 | 1,511 |
| 2020 | $2.3M | 584 | 261 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 479 | 86.4% |
| Consulting Fee | $410,035 | 187 | 8.4% |
| Food and Beverage | $109,131 | 4,261 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $101,475 | 55 | 2.1% |
| Travel and Lodging | $41,206 | 99 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $3,850 | 4 | 0.1% |
| Education | $853.59 | 66 | 0.0% |
Payments by Type
Research
$4.2M
479 transactions
General
$666,551
4,672 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema | BioCryst Pharmaceuticals, Inc. | $1.9M | 0 |
| A Phase 1 Drug Interaction Study to Evaluate the Effects of BCX7353 on the Pharmacokinetics of Two Oral Contraceptives Desogesterel and Combo CC | BioCryst Pharmaceuticals, Inc. | $817,366 | 0 |
| A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLEDOSE, TWO-PERIOD, CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF BCX7353 FORMULATIONS FOR ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA | BioCryst Pharmaceuticals, Inc. | $407,348 | 0 |
| A SINGLE SEQUENCE, OPEN-LABEL, DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF BCX7353 ON CYTOCHROME P450 3A4, 2C9, 2C19 AND 2D6 ENZYME ACTIVITY USING PROBE SUBSTRATES IN HEALTHY SUBJECTS | BioCryst Pharmaceuticals, Inc. | $400,256 | 0 |
| A Phase 3 Randomized Double-blind Placebo-controlled Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema | BioCryst Pharmaceuticals, Inc. | $319,287 | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema | BioCryst Pharmaceuticals, Inc. | $275,344 | 0 |
| A Phase 1 Study drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects | BioCryst Pharmaceuticals, Inc. | $51,402 | 0 |
| A PHASE 1 OPEN-LABEL RANDOMIZED SINGLEDOSE TWO-PERIOD CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF BCX7353 FORMULATIONS FOR ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA | BioCryst Pharmaceuticals, Inc. | $31,234 | 0 |
| A PHASE 1, OPEN-LABEL, TASTE ASSESSMENT OF BEROTRALSTAT LIQUID FORMULATIONS IN HAE SUBJECTS | BioCryst Pharmaceuticals, Inc. | $31,156 | 0 |
Top Doctors Receiving Payments for Orladeyo — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Allergy & Immunology | Tarrytown, NY | $7,330 | 10 |
| , M.D | Allergy & Immunology | Gardner, KS | $7,311 | 8 |
| , MD | Internal Medicine | Charlestown, MA | $6,500 | 2 |
| , MD | Allergy & Immunology | San Diego, CA | $5,464 | 7 |
| , M.D., PH.D | Allergy | San Juan, PR | $4,511 | 9 |
| , MD | Allergy & Immunology | Columbus, OH | $4,157 | 19 |
| , M.D | Allergy & Immunology | Lincoln, NE | $3,980 | 7 |
| , DO | Allergy & Immunology | Northampton, MA | $3,771 | 13 |
| , MD | Allergy & Immunology | Charlotte, NC | $3,712 | 24 |
| , M.D | Allergy & Immunology | San Antonio, TX | $3,594 | 25 |
| , MD, PHD | Allergy | Wheaton, MD | $3,170 | 11 |
| , M.D | Allergy & Immunology | Charlotte, NC | $3,100 | 4 |
| , M.D | Internal Medicine | Layton, UT | $3,040 | 3 |
| , M.D.M.D | Allergy & Immunology | North Charleston, SC | $3,025 | 2 |
| , MD | Infectious Disease | Charlotte, NC | $2,925 | 1 |
| , M.D | Hematology | Los Angeles, CA | $2,750 | 1 |
| , MD DPHIL | Internal Medicine | Charlestown, MA | $2,750 | 1 |
| , M.D | Allergy | Waterbury, CT | $2,647 | 7 |
| , MD | Pediatrics | Chicago, IL | $2,250 | 1 |
| , M.D | Allergy & Immunology | Centennial, CO | $2,010 | 12 |
| , D.O | Allergy & Immunology | Omaha, NE | $1,782 | 18 |
| , M.D | Allergy & Immunology | Seattle, WA | $1,667 | 12 |
| , MD | Dermatology | Redwood City, CA | $1,650 | 1 |
| , MD | Allergy & Immunology | Durham, NC | $1,650 | 1 |
| Michele Columbo | — | Bryn Mawr, PA | $1,572 | 14 |
Ad
Manufacturing Companies
- BioCryst Pharmaceuticals, Inc. $4.3M
- BioCryst US Sales Co., LLC $621,953
Product Information
- Type Drug
- Total Payments $4.9M
- Total Doctors 1,565
- Transactions 5,151
About Orladeyo
Orladeyo is a drug associated with $4.9M in payments to 1,565 healthcare providers, recorded across 5,151 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2020 to 2024. In 2024, $593.29 was paid across 47 transactions to 22 doctors.
The most common payment nature for Orladeyo is "Unspecified" ($4.2M, 86.4% of total).
Orladeyo is associated with 9 research studies, including "An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema" ($1.9M).